控制性降压药物在内镜鼻窦手术中的系统综述与网状Meta分析
该系统综述与网状Meta分析纳入52项随机临床试验共3526例接受内镜鼻窦手术的患者,比较九种降压药物与安慰剂减少术中出血的效果与安全性。结果显示地尔硫䓬、艾司洛尔、右美托咪定、拉贝洛尔和可乐定均可减少出血,右美托咪定降低平均动脉压最显著,艾司洛尔有利于缩短苏醒时间。
要点
- 地尔硫䓬、艾司洛尔、右美托咪定、拉贝洛尔和可乐定均可减少内镜鼻窦手术术中出血。
- 右美托咪定降低术中平均动脉压幅度最大,艾司洛尔和拉贝洛尔可缩短苏醒时间。
- 控制性降压改善手术视野质量且安全性相当。
核心结论
- 控制性降压可改善内镜鼻窦手术的手术视野质量且安全性相当。
- 地尔硫䓬、艾司洛尔、右美托咪定、拉贝洛尔和可乐定均为有效药物。
- 右美托咪定降低平均动脉压最显著,艾司洛尔有利于术后恢复。
研究设计与样本
- 系统综述与网状Meta分析,检索PubMed、Scopus、Web of Science和Cochrane数据库至2024年12月并更新至2025年5月。
- 纳入52项随机临床试验共3526例参与者,其中43项研究纳入网状分析。
- 使用Cochrane偏倚风险评估工具和GRADE框架评价证据质量。
主要发现
- 与安慰剂相比,地尔硫䓬减少出血评分(MD -1.25,95%CI -2.13至-0.37)。
- 艾司洛尔减少出血评分(MD -1.16,95%CI -1.80至-0.51)。
- 右美托咪定减少出血评分(MD -1.09,95%CI -1.48至-0.70)。
- 拉贝洛尔减少出血评分(MD -1.00,95%CI -1.58至-0.42)。
- 可乐定减少出血评分(MD -0.69,95%CI -1.23至-0.16)。
关键数值与推荐
- 右美托咪定降低平均动脉压幅度最大(MD -30.30 mmHg,95%CI -47.91至-12.69)。
- 可乐定降低平均动脉压(MD -28.61,95%CI -53.11至-4.11)。
- 艾司洛尔降低平均动脉压(MD -27.62,95%CI -49.73至-5.51)。
- 拉贝洛尔降低平均动脉压(MD -26.54,95%CI -47.20至-5.87)。
- 60分钟时比索洛尔(MD -58.30 bpm,95%CI -67.50至-49.10)、维拉帕米(MD -49.90 bpm,95%CI -58.98至-40.82)和拉贝洛尔(MD -43.89 bpm,95%CI -54.59至-33.18)心率下降幅度最大。
临床怎么用
- 内镜鼻窦手术中可考虑使用地尔硫䓬、艾司洛尔、右美托咪定、拉贝洛尔或可乐定实施控制性降压以减少出血。
- 需大幅降低平均动脉压时可优先考虑右美托咪定。
- 关注术后恢复速度时可考虑艾司洛尔或拉贝洛尔以缩短苏醒时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Excessive bleeding during endoscopic sinus surgery (ESS) impairs visualization and increases complications. Controlled hypotension is widely used; however, comparative effectiveness of available pharmacological agents remains uncertain. OBJECTIVE: To compare the effectiveness and safety of hypotensive drugs for reduced bleeding in ESS. DATA SOURCES: PubMed, Scopus, Web of Science, and Cochrane databases were searched from inception to December 2024, and updated to include studies up to May 2025. STUDY SELECTION: Randomized clinical trials of patients undergoing ESS and receiving dexmedetomidine, clonidine, esmolol, labetalol, bisoprolol, metoprolol, diltiazem, nifedipine, or verapamil vs placebo. A total of 1258 records were screened. DATA EXTRACTION AND SYNTHESIS: Data were extracted and assessed using the Cochrane risk of bias tool. Certainty was rated using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) framework. A random-effects meta-analysis was conducted in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement guidelines. MAIN OUTCOMES AND MEASURES: Surgical bleeding score, intraoperative mean arterial pressure (MAP), and mean intraoperative heart rate. Secondary outcomes included blood loss, surgery duration, and emergence time. RESULTS: The analysis included 52 randomized clinical trials involving 3526 participants; of these, 43 studies contributed to the network analysis. Several agents were associated with reduced bleeding vs placebo: diltiazem (mean difference [MD], -1.25; 95% CI, -2.13 to -0.37), esmolol (MD, -1.16; 95% CI, -1.80 to -0.51), dexmedetomidine (MD, -1.09; 95% CI, -1.48 to -0.70), labetalol (MD, -1.00; 95% CI, -1.58 to -0.42), and clonidine (MD, -0.69; 95% CI, -1.23 to -0.16). Dexmedetomidine was associated with the most reduced MAP (MD, -30.30 mm Hg; 95% CI, -47.91 to -12.69), followed by clonidine (MD, -28.61; 95% CI, -53.11 to -4.11), esmolol (MD, -27.62; 95% CI, -49.73 to -5.51), and labetalol (MD, -26.54; 95% CI, -47.20 to -5.87). At 60 minutes, bisoprolol (MD, -58.30; 95% CI, -67.50 to -49.10 beats per minute [bpm]), verapamil (MD, -49.90; 95% CI, -58.98 to -40.82 bpm), and labetalol (MD, -43.89; 95% CI, -54.59 to -33.18 bpm) produced the largest heart rate reductions. Esmolol (MD, -3.67; 95% CI, -4.21 to -3.13 minutes) and labetalol (MD, -3.64; 95% CI, -4.79 to -2.49 minutes) shortened emergence time. CONCLUSIONS AND RELEVANCE: In this systematic review and network meta-analysis, controlled hypotension improved surgical field quality in ESS with comparable safety. Diltiazem, esmolol, dexmedetomidine, labetalol, and clonidine were effective; dexmedetomidine was associated with reduced MAP the most, and esmolol favored recovery.
引用
- Saeed A, Saeed O, Nounou MV, et al. Hypotensive Agents for Controlled Hypotension in Endoscopic Sinus Surgery: A Systematic Review and Network Meta-Analysis. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 41609813. doi:10.1001/jamaoto.2025.5222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。